neurodegeneration News
-
Assessing CDM measures in grey matter micro structure in AD Patients for Takeda Pharmaceuticals
Oxford Brain Diagnostics has started a project for Takeda Pharmaceuticals. The project is testing Cortical Disarray Measurement (CDM®) technology as a neurodegeneration biomarker with a view to using it in future clinical trials. Dr Steven Chance, CEO, said ‘we are very excited to be engaged with Takeda on this project using our CDM method on diffusion MRI scans. Alzheimer’s ...
-
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company (“Lilly”) has declared proof of principle for the first two targets in the companies’ exclusive relationship in neurodegeneration and pain, under the companies’ global research and licensing ...
-
TreeFrog Therapeutics back in the FrenchTech120
Already selected in 2020 to join the French government’s program to accelerate the fastest-growing French-based scale-ups, TreeFrog Therapeutics is back in the FrenchTech120 in 2022. Now bringing over 70 biophysicists, stem cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the ...
-
Oxford Brain Diagnostics awarded FDA Breakthrough Device Designation for technology to predict Alzheimer’s Disease
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease Oxford Brain ...
-
Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau Oligomers.” The ‘776 ...
-
DiamiR Announces Oral Presentation at 21st International Conference on Alzheimer`s Drug Discovery
DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Dr. Kira Sheinerman, Chief Executive Officer, will be presenting and participating in a panel discussion at The 21st International Conference on Alzheimer's Drug Discovery hosted by the Alzheimer's Drug Discovery Foundation (ADDF) and held virtually October 5-6, ...
By DiamiR
-
Peer-Reviewed Journal Publishes PrecivityAD™ Blood Test Research, Confirming Its Role in Assisting Clinicians in Alzheimer’s Diagnosis
A peer-reviewed journal has published the first research paper to state that the PrecivityAD™ blood test “can accurately identify brain amyloid status based on a single blood sample.” The research paper in Molecular Neurodegeneration adds that the test’s “excellent performance” for Alzheimer’s disease (AD) diagnosis allows for “improved medical ...
-
Oxford Brain Diagnostics wins funding from the National Institute for Health Research (NIHR) to test Alzheimer’s diagnostic in NHS
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have been awarded funding by the National Institute for Health Research (NIHR) to assess CDM® as a novel and promising tool to identify and predict disease progression amongst patients presenting with mild cognitive impairment ...
-
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market-leading optomap ultra-widefield retinal imaging devices to diagnose ...
By Optos, Inc.
-
Agilent Technologies Completes Acquisition of Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism
Agilent Technologies Inc. today announced it has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics. Agilent announced its intent to acquire Seahorse on Sept. 9. Seahorse's leading technology enables researchers to better understand cell health, function and signaling, and how the cell may be impacted ...
-
Agilent Technologies to Acquire Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism
Agilent Technologies Inc. (NYSE: A) and Seahorse Bioscience today announced they have signed a definitive agreement under which Agilent will acquire Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics. Exploration into cell metabolism is rapidly accelerating as the links between mitochondrial function and disease are increasingly ...
-
Inscopix Expands Applications with Blood Flow Imaging to Study Relationship between Brain Activity and Vascular Dynamics
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other debilitating ...
-
Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has recently closed an ...
-
In-depth Mitochondrial Function Testing Services at Creative Biogene
New York, United States—April 21, 2022—Defects in mitochondrial function have long been suspected of contributing to the development of cancer. In this regard, Creative Biogene strives to explore mitochondrial functions that are yet to be discovered as well as the pathogenesis of mitochondria-associated cancers and possible interventions through in-depth mitochondrial function testing ...
-
ALS research gets a $4.1 million boost from CVS/pharmacy fundraising Campaign
In just 21 days, CVS/pharmacy's ninth annual in-store fundraising campaign to support the fight against amyotrophic lateral sclerosis (ALS) brought in $4.1 million. The funds raised by the campaign will be donated to the Boston-based ALS Therapy Alliance (ATA) to support the funding of new clinical research aimed at developing new therapies for ALS patients and focused on the ultimate goal of ...
-
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants
A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today. The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI. “This ...
By TIKOMED AB
-
Gain Therapeutics Announces Additional Details On Its February 4th Virtual R&D Day
Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable BETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery ...
-
Deep Genomics Appoints Jeffrey M. Brown, Ph.D., Vice President of Preclinical Research
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, Preclinical Research. Jeffrey will be responsible for advancing programs into IND-enabling studies, overseeing the discipline of experimental biology, and working with the leadership team on scientific and business strategies. Fueled by their AI ...
-
Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer’s Disease (CTAD) Conference and Society for Neuroscience Meeting
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference and at the Society for ...
-
Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer’s Disease and Related Tauopathies
Data presented at AAIC demonstrates oral lead product candidate OLX-07010 reduces tau self-association and insoluble tau aggregates Oligomerix to begin clinical testing of OLX-07010 in 2Q22 Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you